Has Pfizer's "enterprise-wide cost realignment program," aimed primarily at optimizing its operational processes, as well as terminating clinical-stage projects where the commercial prospects of ...

With that in mind, let's consider two high-yield dividend stocks worth investing in: Pfizer (NYSE: PFE) and Medical ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

Morgan Stanley maintained an 'overweight' rating on ITC Ltd. with a target price of Rs 500, citing strong topline growth ...

Pfizer has appointed a chief digital officer because of the growing importance of digital technology in R&D and business process, as part of a boardroom shake-up. Last week Pfizer announced that ...

NEW YORK, April 29, 2025--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance(1). NEW YORK, April 26, 2025--Pfizer Inc ...

Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category – but has now decided on a lead candidate. The company said that ...

Pharmaceutical Product Sales: - Moderate decline in Q1, attributed to Pfizer profit share softness and Latin America ... is doing very well in terms of performance. So we had the best turnaround time.

This positive movement reflects investor optimism about the company’s financial turnaround and future growth prospects. The stock’s performance is noteworthy, given the broader market trends ...

This increase may reflect investor optimism about the company’s future prospects and strategic initiatives, as well as confidence in its cash position and production growth. Looking ahead ...